Sorting out AOD 9604s emerging role in research on adiposity, regeneration and beyond
That's quite a headline. The useful story starts with a weight-loss trial in people and a very different experiment in rabbits.
The result that spoils the shortcut
AOD-9604 was made from a small part of human growth hormone. The idea was to explore effects on fat metabolism without using the whole hormone. But the test in people matters more than the idea's appeal.
The report on the human programme describes a main obesity trial that didn't show significant weight loss over placebo, a dummy treatment. The obesity programme used oral AOD-9604 and was stopped after the disappointing result.
The hoped-for benefit wasn't shown in that human test. Calling the compound “targeted” can't change that.
Why researchers were interested
In an experiment in obese mice, the growth-hormone fragment increased fat oxidation and produced weight loss. Fat oxidation means using fat as fuel. That doesn't predict someone's appearance.
“Adiposity” is another word that makes the story sound more complicated than it needs to be. It means body fat. A finding about fat metabolism in mice can make a treatment worth testing in people; it can't tell us the result before that test happens.
The animal finding and disappointing human result belong together. The mouse doesn't get the last word just because its result was more cheerful.
And the regeneration claim?
That comes from a different question. A rabbit knee study tested AOD-9604 in joints with experimentally induced osteoarthritis. Researchers found less cartilage damage than with saline, a salt-water comparison.
Those were rabbit joints, not human joints. It wasn't a weight-loss experiment, either. The sources here contain no published human trial showing AOD-9604 repairs osteoarthritic cartilage.
So “regeneration and beyond” needs a pause. It's fine to be curious about that rabbit result. Keep the animal and body part attached to the claim.
Safety needs a separate answer
The human report found tolerability similar to placebo over the periods studied, up to 24 weeks. That doesn't establish long-term safety, rule out rare harms or cover a different preparation or route. It doesn't turn the weight-loss result into a success.
AOD-9604 isn't FDA-approved. On FDA's page current as of April 22, 2026, it appears among withdrawn nominations with safety concerns still listed. Withdrawal isn't clearance for compounding.
The comparison with tirzepatide puts the human results side by side. It won't pick a treatment for you, but it makes the difference in evidence easier to see.